Evidence map›Paper›PMID 40985744›Full record

ArticleJournal of clinical microbiology2025

Off-label evaluation of the BD MAX MDR-TB assay for rapid diagnosis of rifampicin and isoniazid resistance of

Angela Pires Brandao, Fabiane Maria de Almeida Ferreira, Fernanda Cristina Dos Santos Simeao, Lucilaine Ferrazoli, Erica Chimara, Rosângela Siqueira de Oliveira, Juliana Maira Watanabe Pinhata

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Angela Pires BrandaoNúcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo, Brazil.
Fabiane Maria de Almeida FerreiraNúcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo, Brazil.
Fernanda Cristina Dos Santos SimeaoNúcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo, Brazil.
Lucilaine FerrazoliNúcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo, Brazil.
Erica ChimaraNúcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo, Brazil.
Rosângela Siqueira de OliveiraNúcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo, Brazil.
Juliana Maira Watanabe PinhataNúcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo, Brazil.ORCID 0000-0001-5758-6688

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-resistant tuberculosis (TB) remains a primary global health concern. Multidrug-resistant TB is defined by resistance to at least rifampicin (RIF) and isoniazid (INH), the two key drugs used in TB treatment. The BD MAX Multi-Drug Resistant Tuberculosis (BD MAX) assay is a fully automated real-time PCR platform recommended by the World Health Organization for the initial diagnosis of TB and RIF and INH resistance (RIF-R and INH-R) directly from pulmonary clinical samples. This study aimed to assess the off-label performance of BD MAX in clinical

Indexed as

Antitubercular AgentsDrug Resistance, Multiple, BacterialIsoniazidMolecular Diagnostic TechniquesMycobacterium tuberculosisReal-Time Polymerase Chain ReactionRifampinTuberculosis, Multidrug-ResistantHumansMicrobial Sensitivity TestsMutationProspective StudiesSensitivity and SpecificityAntitubercular AgentsIsoniazidRifampinBD MAX MDR-TBdrug resistanceline probe assaymultidrug-resistant tuberculosisMycobacterium tuberculosis

Identifiers

PMID40985744
PMCPMC12607706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.